|
|
|
Remdesivir ( in clinical study against COVID-19 ) |
is a Star Product of
|
 |
Gilead Sciences, Inc. |
|
|
| General information |
| Registration name: Remdesivir ( in clinical study against COVID-19 ) |
Other product names:
2-Ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate
Remdesivir
Gs5734
|
| CAS number 1809249-37-3 |
|
| EINECS: |
| Formula: |
|
|
| Detailed information on the Star Product |
|
The drug Remdesivir from the California pharmaceutical company Gilead Sciences is in a clinical study against COVID-19 / Coronavirus SARS-CoV-2 ... Statement from CEO media: Gilead - Remdesivir - Covid-19 |
|
|
Information on the supplier
Gilead Sciences, Inc. |
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.
Among other things the product range also includes the drug Atripla, Descovy (HIV / AIDS) and Remdesivir (Ebola / COVID-19)
|
|
|
|
|
|
|
|